ABBOTT, M. see LEATHARD, H.L.
ABUBAKAR, I., ALIYU, S.H., ARUMUGAM, C., USMAN, N.K. & HUNTER, P.R. Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis: 387
ABURUZ, S., HEANEY, L.G., MILLERSHIP, J., GAMBLE, J. & MCELNAY, J. A cross-sectional study evaluating the relationship between cortisol suppression and asthma control in patients with difficult asthma: 110
ACKERS, R., MURRAY, M.L., BESAG, F.M.C. & WONG, I.C.K. Prioritizing children’s medicines for research: a pharmacoepidemiological study of antiepileptic drugs: 689
AGERSØ, H. see TORNØE, C.W.
AGORAM, B., SUTJANDRA, L. & SULLIVAN, J.T. Population pharmacokinetics of darbepoetin alfa in healthy subjects: 41
AKIZAWA, T. see TAKAMA, H.
ALIYU, S.H. see ABUBAKAR, I.
ALLEGAERT, K. see ANDERSON, B.J.
AL-ROOMI, K. see PRASAD, K.
AMIN, D.M. see MANT, T.G.K.
ANDERSON, B.J., ALLEGAERT, K., VAN DEN ANKER, J.N., COSSEY, V. & HOLFORD, N.H.G. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance: 75
AREFAYENE, M. see SHIN, J.-G.
ARONSON, J.K. Adverse drug reactions – no farewell to harms: 131
ARONSON, J.K. Communicating information about drug interactions: 637
ARONSON, J.K. Compliance, concordance, adherence: 383
ARONSON, J.K. Concentration-effect and dose-response relations in clinical pharmacology: 255
ARONSON, J.K. Drug therapy in kidney disease: 509
ARONSON, J.K., LENNARD, M.S., RITTER, J.M., BEGG, E.J., LEWIS, L.D. & SCHACHTER, M. Editors’ review of 2006 and the BJCP prize: 1
ARORA, M. see PRAHARAJ, S.K.
ARUMUGAM, C. see ABUBAKAR, I.
ARUNA, D. & NAIDU, M.U.R. Pharmacodynamic interaction studies of Ginkgo biloba with cilostazol and clopidogrel in healthy human subjects: 333
ASAI, F. see JAKUBOWSKI, J.A.
ASIMUS, S. & GORDI, T. Retrospective analysis of artemisinin pharmacokinetics: application of a semiphysiological autoinduction model: 758
ATTHOBARI, J., GANSEVOORT, R.T., VISSER, S.T., DE JONG, P.E. & de JONG-VAN DEN BERG, L.T.W. The impact of hormonal contraceptives on blood pressure, urinary albumin excretion and glomerular filtration rate: 224
AVERY, A.J. see HOWARD, R.L.
AYDT, E. see MEYER, M.
AZOULAY, L. see BÉRARD, A.
BALAKRISHNAN, K., TORDOFF, J., NORRIS, P. & REITH, D. Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998–2002: 85
BALDESSARINI, R.J. see SIM, K.
BANFIELD, C. see GUPTA, S.
BARBANOJ, M.J. see MOLTÓ, J.
BARSHOP, B.A. see FIDLER, M.C.
BÉRARD, A. see BOUCHARD, M.-H.
BÉRARD, A., AZOULAY, L., KOREN, G., BLAIS, L., PERREAULT, S. & ORAICHI, D. Isotretinoin, pregnancies, abortions and birth defects: a populationbased perspective: 196
BECKA, M. see KUBITZA, D.
BEDDING, A.W. see FORGUE, S.T.
BEEH, K.-M. see MEYER, M.
BEGG, E.J. see ARONSON, J.K.
BEGG, E.J. see VELLA-BRINCAT, J.W.A.
BEIER, J. see MEYER, M.
BELL, S.C. see HENNIG, S.
BENGTSSON, T. see BONDESSON, E.
BENNDORF, R. see KOM, G.D.
BENNETT, K. see USHER, C.
BERTINO, J.S. see CHEN, Y.-C.
BESAG, F.M.C. see ACKERS, R.
BEYER, D. see MEYER, M.
BIANCHETTI, M.G. see MEIER, C.M.
BLACK, J.W. see GERSKOWITCH, V.P.
BLAIS, L. see BÉRARD, A.
BLAIS, L. see BOUCHARD, M.-H.
BLANCO, A. see MOLTÓ, J.
BLENKINSOPP, A., WILKIE, P., WANG, M. & ROUTLEDGE, P.A. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience: 148
BLIX, H.S. see VIKTIL, K.K.
BLUME, H. see NASSR, N.
BÖGER, R.H. see KOM, G.D.
BONDESSON, E., BENGTSSON, T., NILSSON, L.-E. & WOLLMER, P. Site of deposition and absorption of an inhaled hydrophilic solute: 722
BOUCHARD, M.-H., DRAGOMIR, A., BLAIS, L., BÉRARD, A., PILON, D. & PERREAULT, S. Impact of adherence to statins on coronary artery disease in primary prevention: 698
BOUW, R. see VAN HEST, R.M.
BRADFORD, D. see MANT, T.G.K.
BRAMELD, K. see ZHANG, M.
BRAMSON, C. see OUELLET, D.
BRANCH, L.G. see FRENCH, D.D.
BRANCH, R.A. see ZGHEIB, N.K.
BRANDT, J.T. see JAKUBOWSKI, J.A.
BROWNSELL, M. see LEATHARD, H.L.
BRYANT, L. see NGUYEN, N.Q.
BURGER, D.M. see SKOWRON, G.
BURGGRAAF, J. see VAN DOORN, M.
BURGSTAD, C. see NGUYEN, N.Q.
CAFFO, B. see NDOVI, T.T.
CAMPA, C. see COSTAGLIOLA, C.
CAMPBELL, R. see FRENCH, D.D.
CHAMBERS, S.T. see VELLA-BRINCAT, J.W.A.
CHAN, C., YEO, K.P., PAN, A.X., LIM, M., KNADLER, M.P. & SMALL, D.S. Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects: 310
CHAN, Y.H. see SIM, K.
CHAPMAN, M. see NGUYEN, N.Q.
CHARLES, B.G. see HENNIG, S.
CHARMES, J.-P. see LAROCHE, M.-L.
CHEN, Y.-C., NAFZIGER, A.N., BERTINO, J.S. & KASHUBA, A.D.M. Authors’ response: Poor correlation between 6β-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity: a comment: 633
CHIU, Y.-Y., ROTH, M.D., KOLIS, S., ROGOVITZ, D. & DAVIES, B. Pharmacokinetics of a novel agent, R667, in patients with emphysema: 527
CHO, K.-H. see SHIN, J.-G.
CHOI, L. see NDOVI, T.T.
CHONG, K.T., HO, W.F., KOO, S.H., THOMPSON, P. & LEE, E.J.D. Distribution of the FcγRIIIa 176 F/V polymorphism amongst healthy Chinese, Malays and Asian Indians in Singapore: 328
CHONG, M.-Y. see SIM, K.
CHUA, H.C. see SIM, K.
CHUNG, E.K. see SIM, K.
CLARKE, S.J. see LI, K.M.
CLEUREN, G. see DOBRE, D.
CLOTET, B. see MOLTÓ, J.
COCHAT, P. see NGUYEN, K.-A.
COHEN, A. see VAN DOORN, M.
COMBS, M. see STYPINSKI, D.
CONIL, J.M., GEORGES, B., FOURCADE, O., SEGUIN, T., LAVIT, M., SAMII, K., HOUIN, G., TACK, I. & SAIVIN, S. Assessment of renal function in clinical practice at the bedside of burn patients: 583
CONNELL, J. see SARGENTINI-MAIER, M.L.
CONSTABLE, S., HAM, A. & PIRMOHAMED, M. Herbal medicines and acute medical emergency admissions to hospital: 247
COSSEY, V. see ANDERSON, B.J.
COSTAGLIOLA, C., CAMPA, C., PARMEGGIANI, F., INCORVAIA, C., PERRI, P., D’ANGELO, S., LAMBERTI, G. & SEBASTIANI, A. Effect of 2% dorzolamide on retinal blood flow: a study on juvenile primary open-angle glaucoma patients already receiving 0.5% timolol: 376
CUNNINGHAM, F. see FRENCH, D.D.
CURRIE, G.P., NIRUBAN, A. & DEMPSEY, O.J. A rare cause of finger clubbing in a life-long nonsmoker: 252
CUTLER, D. see GUPTA, S.
D’ANGELO, S. see COSTAGLIOLA, C.
DAVIES, B. see CHIU, Y.-Y.
DAY, R.O. see MINERS, J.O.
DE BRUIN, M.L., LANGENDIJK, P.N.J., KOOPMANS, R.P., WILDE, A.A.M., LEUFKENS, H.G.M. & HOES, A.W. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs: 216
DE JONG, P.E. see ATTHOBARI, J.
DE JONG-VAN DEN BERG, L.T.W. see ATTHOBARI, J.
DE PONTI, F. see POLUZZI, E.
DE SMET, P.A.G.M. Clinical risk management of herb–drug interactions: 258
DEJONGSTE, M.J.L. see DOBRE, D.
DELAVARGA, M. see MOLTÓ, J.
DEMPSEY, O.J. see CURRIE, G.P.
DEUTSCH, R. see FIDLER, M.C.
DI MARCO, M. see MARIER, J.-F.
DOBRE, D., DEJONGSTE, M.J.L., LUCAS, C., CLEUREN, G., VAN VELDHUISEN, D.J., RANCHOR, A.V. & HAAIJER-RUSKAMP, F. Effectiveness of β-blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age?: 356
DOHIL, R. see FIDLER, M.C.
DRAGOMIR, A. see BOUCHARD, M.-H.
DUFFULL, S.B. see HENNIG, S.
ECCLES, R. Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse: 10
ELLINGTON, C., GRGURINOVICH, N., MINERS, J.O. & MANGONI, A.A. Quality of requests for serum digoxin concentrations: experience from an Australian Regional Health Service: 623
ERB, K.A. see NASSR, N.
FEELY, J. see USHER, C.
FENSKE, M. Poor correlation between 6β-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity: a comment: 632
FIDLER, M.C., BARSHOP, B.A., GANGOITI, J.A., DEUTSCH, R., MARTIN, M., SCHNEIDER, J.A. & DOHIL, R. Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion: 36
FIGUERAS, A. see MALDONADO, J.-C.
FLANAGAN, R. see TIMBRELL, J.
FLOCKHART, D.A. see SHIN, J.-G.
FORGUE, S.T., PHILLIPS, D.L., BEDDING, A.W., PAYNE, C.D., JEWELL, H., PATTERSON, B.E., WRISHKO, R.E. & MITCHELL, M.I. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics: 24
FOSSALI, E. see MEIER, C.M.
FOURCADE, O. see CONIL, J.M.
FRANCE, M. see HENNIG, S.
FRASER, R.J. see NGUYEN, N.Q.
FREDRIKSON, H. see LILJA, J.J.
FREESTONE, S. see JAKUBOWSKI, J.A.
FRENCH, D.D., CAMPBELL, R., SPEHAR, A., RUBENSTEIN, L.Z., BRANCH, L.G. & CUNNINGHAM, F. National outpatient medication profiling: medications associated with outpatient fractures in community-dwelling elderly veterans: 238
FRYE, R.F. see ZGHEIB, N.K.
FUJII, S. see SIM, K.
FUMAZ, C.R. see MOLTÓ, J.
GALLAGHER, K. see VELLA-BRINCAT, J.W.A.
GAMBLE, J. see ABURUZ, S.
GANGOITI, J.A. see FIDLER, M.C.
GANSEVOORT, R.T. see ATTHOBARI, J.
GARDNER, M. see OUELLET, D.
GEORGE, J. & SHALANSKY, S.J. Predictors of refill non-adherence in patients with heart failure: 488
GEORGE, J., MUNRO, K., MCCAIG, D. & STEWART, D. Risk factors for medication misadventure among residents in sheltered housing complexes: 171
GEORGES, B. see CONIL, J.M.
GERSKOWITCH, V.P., HODGE, J., HULL, R.A.D., SHANKLEY, N.P., KALINDJIAN, S.B., MCEWEN, J. & BLACK, J.W. Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist: 618
GHIGLIA, S. see MEIER, C.M.
GIRBES, A.R.J. see VAN ZANTEN, A.R.H.
GOGGIN, T. see VAN HEST, R.M.
GOMENI, R. & MERLO-PICH, E. Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials: 595
GORDI, T. see ASIMUS, S.
GORDON, R. see VAN HEST, R.M.
GRGURINOVICH, N. see ELLINGTON, C.
GRIBNAU, F.W.J. see VAN LUIJN, J.C.F.
GUDE, N.M. see SUDHAKARAN, S.
GUEYFFIER, F. see NGUYEN, K.-A.
GUO, R.-C. see SUN, D.-Q.
GUPTA, S., JEN, J., KOLZ, K. & CUTLER, D. Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia: 292
GUPTA, S., KHALILIEH, S., KANTESARIA, B. & BANFIELD, C. Pharmacokinetics of desloratadine in children between 2 and 11 years of age: 534
HAAIJER-RUSKAMP, F. see DOBRE, D.
HACKETT, L.P. see ILETT, K.F.
HACKETT, L.P. see KRISTENSEN, J.H.
HALL, J.M. The BPS Diploma in Advanced Pharmacology: a training opportunity for clinical pharmacologists: 385
HALL, W. see MANT, A.
HAM, A. see CONSTABLE, S.
HAWKEY, C.J. Authors’ reply: Nonselective nonsteroidal anti-inflammatory drugs and increased cardiovascular events: stress could be the explanation: 502
HAYASHI, N., TSUKAMOTO, Y., SALLAS, W.M. & LOWE, P.J. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab: 548
HAZUI, T. see HORI, S.
HE, Y.L. see SIM, K.
HEANEY, L.G. see ABURUZ, S.
HENDRIX, C.W. see NDOVI, T.T.
HENNIG, S., WATERHOUSE, T.H., BELL, S.C., FRANCE, M., WAINWRIGHT, C.E., MILLER, H., CHARLES, B.G. & DUFFULL, S.B. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients: 438
HERMANN, R. see NASSR, N.
HIROTA, T. see JAKUBOWSKI, J.A.
HO, W.F. see CHONG, K.T.
HODGE, J. see GERSKOWITCH, V.P.
HOES, A.W. see DE BRUIN, M.L.
HOGG, J.S. see MULRENNAN, S.A.
HOLFORD, N.H.G. see ANDERSON, B.J.
HOLLOWAY, R.H. see NGUYEN, N.Q.
HOLMAN, C.D.J. see ZHANG, M.
HOLOHAN, P.D. see LAROCCA, D.
HORI, S., MATSUO, N., YAMAMOTO, A., HAZUI, T., YAGI, H., NAKANO, M., SUZUKI, Y., MIKI, A., OHTANI, H. & SAWADA, Y. Piloerection induced by replacing fluvoxamine with milnacipran: 665
HOSKINS, J. see LI, K.M.
HOUIN, G. see CONIL, J.M.
HOWARD, R.L., AVERY, A.J., SLAVENBURG, S., ROYAL, S., PIPE, G., LUCASSEN, P. & PIRMOHAMED, M. Which drugs cause preventable admissions to hospital? A systematic review: 136
HU, P. see ZHAO, Q.
HULL, R.A.D. see GERSKOWITCH, V.P.
HUNTER, P.R. see ABUBAKAR, I.
ILETT, K.F. see KRISTENSEN, J.H.
ILETT, K.F., HACKETT, L.P., KRISTENSEN, J.H. & KOHAN, R. Transfer of dexamphetamine into breast milk during treatment for attention deficit hyperactivity disorder: 371
INCORVAIA, C. see COSTAGLIOLA, C.
ISHIKAWA, H. see STYPINSKI, D.
ITO, K., OHTANI, H. & SAWADA, Y. Assessment of α1-adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory: 394
IVERSEN, L. & WHELPTON, R. Speed, Ecstasy, Ritalin: The Science of Amphetamines: 763
JACOBS, T. see SARGENTINI-MAIER, M.L.
JAKUBOWSKI, J.A., MATSUSHIMA, N., ASAI, F., NAGANUMA, H., BRANDT, J.T., HIROTA, T., FREESTONE, S. & WINTERS, K.J. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans: 421
JEN, J. see GUPTA, S.
JEWELL, H. see FORGUE, S.T.
JHAJ, R. see SADASIVAM, B.
JIANG, J. see ZHAO, Q.
JILMA, B. see MEYER, M.
JONSSON, E.N. see TORNØE, C.W.
KALINDJIAN, S.B. see GERSKOWITCH, V.P.
KAMBAYASHI, Y. see MANT, T.G.K.
KANG, W.-K. see SHIN, J.-G.
KANTESARIA, B. see GUPTA, S.
KARLSSON, M.O. see TORNØE, C.W.
KASHUBA, A.D.M. see CHEN, Y.-C.
KASSAÏ, B. see NGUYEN, K.-A.
KHALILIEH, S. see GUPTA, S.
KIM, D.-I. see SHIN, J.-G.
KIM, D.-S. see SHIN, J.-G.
KIM, K.-A. see SHIN, J.-G.
KIM, K.-A., PARK, P.-W. & PARK, J.-Y. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects: 53
KIM, K.-A., PARK, P.-W., KIM, K.R. & PARK, J.-Y. Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans: 339
KIM, K.R. see KIM, K.-A.
KIRKPATRICK, C.M.J. see VELLA-BRINCAT, J.W.A.
KNADLER, M.P. see CHAN, C.
KNIGHTS, K.M., MANGONI, A.A. & MINERS, J.O. Authors’ reply: Nonselective nonsteroidal anti-inflammatory drugs and increased cardiovascular events: emotional stress could be the explanation: 502
KNOERZER, D. see NASSR, N.
KOHAN, R. see ILETT, K.F.
KOHAN, R. see KRISTENSEN, J.H.
KOLIS, S. see CHIU, Y.-Y.
KOLZ, K. see GUPTA, S.
KOM, G.D., SCHWEDHELM, E., MAAS, R., SCHNEIDER, L., BENNDORF, R. & BÖGER, R.H. Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F2trans-isoprostane in hypercholesterolaemic patients: 672
KONG, D.C.M. see SUDHAKARAN, S.
KOO, S.H. see CHONG, K.T.
KOOPMANS, R.P. see DE BRUIN, M.L.
KOREN, G. see BÉRARD, A.
KOSHIKAWA, S. see TAKAMA, H.
KRISHNAN, P.R. see PRASAD, K.
KRISTENSEN, J.H. see ILETT, K.F.
KRISTENSEN, J.H., ILETT, K.F., RAMPONO, J., KOHAN, R. & HACKETT, L.P. Transfer of the antidepressant mirtazapine into breast milk: 322
KUBITZA, D., BECKA, M., MUECK, W. & ZUEHLSDORF, M. Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen: 469
KUYPERS, D. see NAESENS, M.
LACOURCIERE, Y. see LEFEBVRE, J.
LAHEIJ, R.J.F. see VAN OIJEN, M.G.H.
LAHU, G. see NASSR, N.
LAINE, K. see SAARI, T.I.
LAMBERTI, G. see COSTAGLIOLA, C.
LANGENDIJK, P.N.J. see DE BRUIN, M.L.
LAROCCA, D., LEHMANN, D.F., PERL, A., OZAWA, T. & HOLOHAN, P.D. The combination of nuclear and mitochondrial mutations as a risk factor for idiosyncratic toxicity: 249
LAROCHE, M.-L., CHARMES, J.-P., NOUAILLE, Y., PICARD, N. & MERLE, L. Is inappropriate medication use a major cause of adverse drug reactions in the elderly?: 177
LAVIT, M. see CONIL, J.M.
LAW, M.R., MORRIS, J.K. & WALD, N.J. Calcium channel blockers and headache: 157
LEATHARD, H.L., ABBOTT, M., BROWNSELL, M., LENNARD, M. & MAXWELL, S. Education for new prescribers: a summary of the proceedings of a symposium held at The British Pharmacological Society, December 2005: 5
LEE, E.J.D. see CHONG, K.T.
LEE, M.S. see SIM, K.
LEE, N.B. see SIM, K.
LEFEBVRE, J., POIRIER, L., POIRIER, P., TURGEON, J. & LACOURCIERE, Y. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension: 575
LEHMANN, D.F. see LAROCCA, D.
LEINO, K. see SAARI, T.I.
LENNARD, M. see LEATHARD, H.L.
LENNARD, M. see PHILLIPS, I.R.
LENNARD, M.S. see ARONSON, J.K.
LEUFKENS, H.G.M. see DE BRUIN, M.L.
LEUFKENS, H.G.M. see VAN LUIJN, J.C.F.
LEWIS, L.D. see ARONSON, J.K.
LI, J. see SUDHAKARAN, S.
LI, K.M., RIVORY, L.P., HOSKINS, J., SHARMA, R. & CLARKE, S.J. Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients: 67
LI, X.M. see ZHAO, Q.
LILJA, J.J., NIEMI, M., FREDRIKSON, H. & NEUVONEN, P.J. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide: 732
LIM, M. see CHAN, C.
LIMONI, C. see MEIER, C.M.
LOR, M. see MARIER, J.-F.
LOWE, P.J. see HAYASHI, N.
LOWINGER, J. see MANT, A.
LU, Z.S. see ZHAO, Q.
LUCAS, C. see DOBRE, D.
LUCASSEN, P. see HOWARD, R.L.
MAAS, R. see KOM, G.D.
MADSEN, H. see TORNØE, C.W.
MAHENDRAN, R. see SIM, K.
MALDONADO, J.-C., MELÉNDEZ, S.D. & FIGUERAS, A. Long-term effects of an educational intervention on selfmedication and appropriate drug use in single-sex secondary public schools, Quito, Ecuador: 92
MAMELOK, R.D. see VAN HEST, R.M.
MANGONI, A.A. see ELLINGTON, C.
MANGONI, A.A. see KNIGHTS, K.M.
MANGONI, A.A. see NGUYEN, N.Q.
MANT, A., LOWINGER, J., HALL, W., WHICKER, S., RINGLAND, C. & Stark, H. Statins down under: 125
MANT, T.G.K., BRADFORD, D., AMIN, D.M., PISUPATI, J., KAMBAYASHI, Y., YANO, Y., TANAKA, K. & YAMADA-SAWADA, T. Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers: 512
MARCHESINI, G. see POLUZZI, E.
MARIER, J.-F., LOR, M., MORIN, J., ROUX, L., DI MARCO, M., MORELLI, G. & SÆDDER, E.A. Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation: 121
MARIGNIER, S. see NGUYEN, K.-A.
MARTIN, M. see FIDLER, M.C.
MATHOT, R.A. see VAN HEST, R.M.
MATSUO, N. see HORI, S.
MATSUSHIMA, N. see JAKUBOWSKI, J.A.
MAXWELL, S. see LEATHARD, H.L.
MCCAIG, D. see GEORGE, J.
MCELNAY, J. see ABURUZ, S.
MCEWEN, J. see GERSKOWITCH, V.P.
MCQUAY, H.J. & MOORE, R.A. Dose–response in direct comparisons of different doses of aspirin, ibuprofen and paracetamol (acetaminophen) in analgesic studies: 271
MEIER, C.M., SIMONETTI, G.D., GHIGLIA, S., FOSSALI, E., SALICE, P., LIMONI, C. & BIANCHETTI, M.G. Palatability of angiotensin II antagonists among nephropathic children: 628
MELÉNDEZ, S.D. see MALDONADO, J.-C.
MERLE, L. see LAROCHE, M.-L.
MERLO-PICH, E. see GOMENI, R.
MEYER, M., BEEH, K.-M., BEIER, J., BEYER, D., AYDT, E., ZAHLTEN, R., JILMA, B. & WOLFF, G. Tolerability and pharmacokinetics of inhaled bimosiamose disodium in healthy males: 451
MIKI, A. see HORI, S.
MILLER, H. see HENNIG, S.
MILLERSHIP, J. see ABURUZ, S.
MILTON, A. see OUELLET, D.
MINERS, J.O. & DAY, R.O. Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymes: 380
MINERS, J.O. see ELLINGTON, C.
MINERS, J.O. see KNIGHTS, K.M.
MIRANDA, C. see MOLTÓ, J.
MIRANDA, J. see MOLTÓ, J.
MITCHELL, M.I. see FORGUE, S.T.
MOGER, T.A. see VIKTIL, K.K.
MOLTÓ, J., BLANCO, A., MIRANDA, C., MIRANDA, J., PUIG, J., VALLE, M., DELAVARGA, M., FUMAZ, C.R., BARBANOJ, M.J. & CLOTET, B. Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice: 715
MONTANARO, N. see POLUZZI, E.
MOORE, R.A. see MCQUAY, H.J.
MORELLI, G. see MARIER, J.-F.
MORICE, A.H. see MULRENNAN, S.A.
MORIN, J. see MARIER, J.-F.
MORRIS, J.K. see LAW, M.R.
MOTOLA, D. see POLUZZI, E.
MUECK, W. see KUBITZA, D.
MULRENNAN, S.A., HOGG, J.S., TEOH, R.C. & MORICE, A.H. Adrenal axis suppression unrelated to the dynamics of dosing with beclomethasone monopropionate: 288
MUNRO, K. see GEORGE, J.
MURRAY, M.L. see ACKERS, R.
NAESENS, M., VERBEKE, K., VANRENTERGHEM, Y. & KUYPERS, D. Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients: 541
NAFZIGER, A.N. see CHEN, Y.-C.
NAGANUMA, H. see JAKUBOWSKI, J.A.
NAIDU, M.U.R. see ARUNA, D.
NAKANO, M. see HORI, S.
NAKASHIMA, D. see TAKAMA, H.
NASSR, N., LAHU, G., VON RICHTER, O., REUTTER, F., KNOERZER, D., ZECH, K., ERB, K.A., SCHUG, B., BLUME, H. & HERMANN, R. Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects: 365
NATION, R.L. see SUDHAKARAN, S.
NDOVI, T.T., PARSONS, T., CHOI, L., CAFFO, B., ROHDE, C. & HENDRIX, C.W. A new method to estimate quantitatively seminal vesicle and prostate gland contributions to ejaculate: 404
NEUVONEN, P.J. see LILJA, J.J.
NEUVONEN, P.J. see SAARI, T.I.
NEWBOLD, P., SANDERS, N. & REELE, S.B. Lack of correlation between exercise and sibenadet-induced changes in heart rate corrected measurement of the QT interval: 279
NGUYEN, K.-A., VIAL, T., GUEYFFIER, F., MARIGNIER, S., COCHAT, P. & KASSAÏ, B. Safety of computerized drug management: a case report: 245
NGUYEN, N.Q., MANGONI, A.A., FRASER, R.J., CHAPMAN, M., BRYANT, L., BURGSTAD, C. & HOLLOWAY, R.H. Prokinetic therapy with erythromycin has no significant impact on blood pressure and heart rate in critically ill patients: 498
NI, M.-Y. see SUN, D.-Q.
NIELSEN, H.A. see TORNØE, C.W.
NIEMI, M. see LILJA, J.J.
NILSSON, L.-E. see BONDESSON, E.
NIRUBAN, A. see CURRIE, G.P.
NOHLMANS-PAULSSEN, M.K.E. see VAN ZANTEN, A.R.H.
NORRIS, P. see BALAKRISHNAN, K.
NOUAILLE, Y. see LAROCHE, M.-L.
OBAIDI, M. see STYPINSKI, D.
OGATA, H. see TAKAMA, H.
OGDEN, R. see SKOWRON, G.
OHTANI, H. see HORI, S.
OHTANI, H. see ITO, K.
OLKKOLA, K.T. see SAARI, T.I.
ORAICHI, D. see BÉRARD, A.
OUDIJK, M. see VAN ZANTEN, A.R.H.
OUELLET, D., BRAMSON, C., ROMAN, D., REMMERS, A.E., RANDINITIS, E., MILTON, A. & GARDNER, M. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene: 59
OZAWA, T. see LAROCCA, D.
PAN, A.X. see CHAN, C.
PARK, J.-Y. see KIM, K.-A.
PARK, J.-Y. see KIM, K.-A.
PARK, P.-W. see KIM, K.-A.
PARK, P.-W. see KIM, K.-A.
PARMEGGIANI, F. see COSTAGLIOLA, C.
PARSONS, T. see NDOVI, T.T.
PATTERSON, B.E. see FORGUE, S.T.
PAYNE, C.D. see FORGUE, S.T.
PERL, A. see LAROCCA, D.
PERREAULT, S. see BÉRARD, A.
PERREAULT, S. see BOUCHARD, M.-H.
PERRI, P. see COSTAGLIOLA, C.
PETERS, W.H.M. see VAN OIJEN, M.G.H.
PHILLIPS, D.L. see FORGUE, S.T.
PHILLIPS, I.R. SHEPHARD, E.A. & LENNARD, M. Cytochrome P450 Protocols, 2nd edn: 764
PICARD, N. see LAROCHE, M.-L.
PIGEOLET, E. see SARGENTINI-MAIER, M.L.
PILON, D. see BOUCHARD, M.-H.
PIPE, G. see HOWARD, R.L.
PIRMOHAMED, M. see CONSTABLE, S.
PIRMOHAMED, M. see HOWARD, R.L.
PISUPATI, J. see MANT, T.G.K.
PO, A.L.W. Dose–response of minor analgesics in acute pain: 268
POIRIER, L. see LEFEBVRE, J.
POIRIER, P. see LEFEBVRE, J.
POLDERMAN, K.H. see VAN ZANTEN, A.R.H.
POLS, H.A.P. see VAN DER VELDE, N.
POLUZZI, E., STRAHINJA, P., VACCHERI, A., VARGIU, A., SILVANI, M.C., MOTOLA, D., MARCHESINI, G., DE PONTI, F. & MONTANARO, N. Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage: 346
PRAHARAJ, S.K. & ARORA, M. Amitriptyline for clozapine-induced nocturnal enuresis and sialorrhoea: 128
PRASAD, K., KRISHNAN, P.R., AL-ROOMI, K. & SEQUEIRA R. Anticonvulsant therapy for status epilepticus: 640
PREEN, D.B. see ZHANG, M.
PUIG, J. see MOLTÓ, J.
RAMPONO, J. see KRISTENSEN, J.H.
RANCHOR, A.V. see DOBRE, D.
RANDINITIS, E. see OUELLET, D.
RAYNER, C.R. see SUDHAKARAN, S.
REELE, S.B. see NEWBOLD, P.
REIKVAM, A. see VIKTIL, K.K.
REITH, D. see BALAKRISHNAN, K.
REMMERS, A.E. see OUELLET, D.
REUTTER, F. see NASSR, N.
RIETHUISEN, J.-M. see SARGENTINI-MAIER, M.L.
RINGLAND, C. see MANT, A.
RITTER, J.M. see ARONSON, J.K.
RIVORY, L.P. see LI, K.M.
ROGOVITZ, D. see CHIU, Y.-Y.
ROHDE, C. see NDOVI, T.T.
ROLAN, P. see SARGENTINI-MAIER, M.L.
ROMAN, D. see OUELLET, D.
ROMKES, M. see ZGHEIB, N.K.
ROTH, M.D. see CHIU, Y.-Y.
ROUTLEDGE, P.A. see BLENKINSOPP, A.
ROUX, L. see MARIER, J.-F.
ROYAL, S. see HOWARD, R.L.
RUBENSTEIN, L.Z. see FRENCH, D.D.
SÆDDER, E.A. see MARIER, J.-F.
SAARI, T.I., LAINE, K., LEINO, K., VALTONEN, M., NEUVONEN, P.J. & OLKKOLA, K.T. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects: 116
SADASIVAM, B. & JHAJ, R. Dysgeusia with amlodipine – a case report: 253
SAINZ-FUERTES, R. Robert William Kerwin: 765
SAIVIN, S. see CONIL, J.M.
SALICE, P. see MEIER, C.M.
SALLAS, W.M. see HAYASHI, N.
SAMII, K. see CONIL, J.M.
SANDERS, N. see NEWBOLD, P.
SARGENTINI-MAIER, M.L., ROLAN, P., CONNELL, J., TYTGAT, D., JACOBS, T., PIGEOLET, E., RIETHUISEN, J.-M. & STOCKIS, A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males: 680
SARTORIUS, N. see SIM, K.
SAWADA, Y. see HORI, S.
SAWADA, Y. see ITO, K.
SCHACHTER, M. see ARONSON, J.K.
SCHNEIDER, J.A. see FIDLER, M.C.
SCHNEIDER, L. see KOM, G.D.
SCHUG, B. see NASSR, N.
SCHWEDHELM, E. see KOM, G.D.
SEBASTIANI, A. see COSTAGLIOLA, C.
SEGUIN, T. see CONIL, J.M.
SENDEROVITZ, T. see TORNØE, C.W.
SEQUEIRA R. see PRASAD, K.
SHALANSKY, S.J. see GEORGE, J.
SHANKLEY, N.P. see GERSKOWITCH, V.P.
SHARMA, R. see LI, K.M.
SHEPHARD, E.A. see PHILLIPS, I.R.
SHIN, J.-G., KANG, W.-K., SHON, J.-H., AREFAYENE, M., YOON, Y.-R., KIM, K.-A., KIM, D.-I., KIM, D.-S., CHO, K.-H., WOOSLEY, R.L. & FLOCKHART, D.A. Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects: 206
SHINFUKU, N. see SIM, K.
SHON, J.-H. see SHIN, J.-G.
SI, T. see SIM, K.
SILVANI, M.C. see POLUZZI, E.
SIM, K., LEE, N.B., CHUA, H.C., MAHENDRAN, R., FUJII, S., YANG, S.-Y., CHONG, M.-Y., SI, T., HE, Y.L., LEE, M.S., SUNG, K.M., CHUNG, E.K., CHAN, Y.H., SHINFUKU, N., TAN, C.H., SARTORIUS, N. & BALDESSARINI, R.J. Newer antidepressant drug use in East Asian psychiatric treatment settings: REAP (Research on East Asia Psychotropic Prescriptions) Study: 431
SIMONETTI, G.D. see MEIER, C.M.
SKOWRON, G., OGDEN, R. & BURGER, D.M. Reverse transcriptase inhibitors in HIV/AIDS therapy: 634
SLAVENBURG, S. see HOWARD, R.L.
SMALL, D.S. see CHAN, C.
SPEHAR, A. see FRENCH, D.D.
STARK, H. see MANT, A.
STEWART, A.J. see STYPINSKI, D.
STEWART, D. see GEORGE, J.
STOCKIS, A. see SARGENTINI-MAIER, M.L.
STRAHINJA, P. see POLUZZI, E.
STRICKER, B.H.C. see VAN DER VELDE, N.
STYPINSKI, D., OBAIDI, M., COMBS, M., WEBER, M., STEWART, A.J. & ISHIKAWA, H. Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers: 459
SUDHAKARAN, S., RAYNER, C.R., LI, J., KONG, D.C.M., GUDE, N.M. & NATION, R.L. Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma: 315
SULLIVAN, J.T. see AGORAM, B.
SUN, D.-Q., WANG, H.-S., NI, M.-Y., WANG, B.-J. & GUO, R.-C. Pharmacokinetics, safety and tolerance of single- and multiple-dose adefovir dipivoxil in healthy Chinese subjects: 15
SUNG, K.M. see SIM, K.
SUTJANDRA, L. see AGORAM, B.
SUTTON, J.A. Nonselective nonsteroidal anti-inflammatory drugs and increased cardiovascular events: stress could be the explanation: 501
SUZUKI, Y. see HORI, S.
TACK, I. see CONIL, J.M.
TAKAMA, H., TANAKA, H., NAKASHIMA, D., OGATA, H., UCHIDA, E., AKIZAWA, T. & KOSHIKAWA, S. Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration: 300
TAN, C.H. see SIM, K.
TANAKA, H. see TAKAMA, H.
TANAKA, K. see MANT, T.G.K.
TAS, A. see VAN DOORN, M.
TEELING, M. see USHER, C.
TEOH, R.C. see MULRENNAN, S.A.
THOMPSON, P. see CHONG, K.T.
TIMBRELL, J. & FLANAGAN, R. The Poison Paradox: 254
TORDOFF, J. see BALAKRISHNAN, K.
TORNØE, C.W., AGERSØ, H., SENDEROVITZ, T., NIELSEN, H.A., MADSEN, H., KARLSSON, M.O. & JONSSON, E.N. Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic–pituitary–gonadal axis following treatment with GnRH analogues: 648
TRACY, T.S. see ZGHEIB, N.K.
TSUKAMOTO, Y. see HAYASHI, N.
TURGEON, J. see LEFEBVRE, J.
TYTGAT, D. see SARGENTINI-MAIER, M.L.
UCHIDA, E. see TAKAMA, H.
USHER, C., BENNETT, K., TEELING, M. & FEELY, J. Characterizing new users of NSAIDs before and after rofecoxib withdrawal: 494
USMAN, N.K. see ABUBAKAR, I.
VACCHERI, A. see POLUZZI, E.
VALLE, M. see MOLTÓ, J.
VALTONEN, M. see SAARI, T.I.
VAN DEN ANKER, J.N. see ANDERSON, B.J.
VAN DER CAMMEN, T.J.M. see VAN DER VELDE, N.
VAN DER GREEF, J. see VAN DOORN, M.
VAN DER MEER, Y.G. see VAN ZANTEN, A.R.H.
VAN DER VELDE, N., CH. STRICKER, B.H.C., POLS, H.A.P. & VAN DER CAMMEN, T.J.M. Risk of falls after withdrawal of fall-risk-increasing drugs: a prospective cohort study: 232
VAN DOORN, M., VOGELS, J., TAS, A., VAN HOOGDALEM, E.J., BURGGRAAF, J., COHEN, A. & VAN DER GREEF, J. Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers: 562
VAN GELDER, T. see VAN HEST, R.M.
VAN HEST, R.M., VAN GELDER, T., BOUW, R., GOGGIN, T., GORDON, R., MAMELOK, R.D. & MATHOT, R.A. Time-dependent clearance of mycophenolic acid in renal transplant recipients: 741
VAN HOOGDALEM, E.J. see VAN DOORN, M.
VAN LUIJN, J.C.F., GRIBNAU, F.W.J. & LEUFKENS, H.G.M. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization: 159
VAN OIJEN, M.G.H., LAHEIJ, R.J.F. & PETERS, W.H.M. Authors’ response: Relationships between the adverse effects of aspirin and polymorphisms in genes encoding aspirin metabolizing enzymes: 381
VAN VELDHUISEN, D.J. see DOBRE, D.
VAN ZANTEN, A.R.H., OUDIJK, M., NOHLMANS-PAULSSEN, M.K.E., VAN DER MEER, Y.G., GIRBES, A.R.J. & POLDERMAN, K.H. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/ pharmacodynamics, bacterial susceptibility and clinical efficacy: 100
VANRENTERGHEM, Y. see NAESENS, M.
VARGIU, A. see POLUZZI, E.
VELLA-BRINCAT, J.W.A., BEGG, E.J., KIRKPATRICK, C.M.J., ZHANG, M., CHAMBERS, S.T. & GALLAGHER, K. Protein binding of cefazolin is saturable in vivo both between and within patients: 753
VERBEKE, K. see NAESENS, M.
VIAL, T. see NGUYEN, K.-A.
VIKTIL, K.K., BLIX, H.S., MOGER, T.A. & REIKVAM, A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems: 187
VISSER, S.T. see ATTHOBARI, J.
VITRY, A.I. Comparative assessment of four drug interaction compendia: 709
VOGELS, J. see VAN DOORN, M.
VON RICHTER, O. see NASSR, N.
WAINWRIGHT, C.E. see HENNIG, S.
WALD, N.J. see LAW, M.R.
WANG, B.-J. see SUN, D.-Q.
WANG, H.-S. see SUN, D.-Q.
WANG, M. see BLENKINSOPP, A.
WATERHOUSE, T.H. see HENNIG, S.
WEBER, M. see STYPINSKI, D.
WHELPTON, R. see IVERSEN, L.
WHICKER, S. see MANT, A.
WILDE, A.A.M. see DE BRUIN, M.L.
WILKIE, P. see BLENKINSOPP, A.
WINTERS, K.J. see JAKUBOWSKI, J.A.
WOLFF, G. see MEYER, M.
WOLLMER, P. see BONDESSON, E.
WONGP, I.C.K. see ACKERS, R.
WOOSLEY, R.L. see SHIN, J.-G.
WRISHKO, R.E. see FORGUE, S.T.
YAGI, H. see HORI, S.
YAMADA-SAWADA, T. see MANT, T.G.K.
YAMAMOTO, A. see HORI, S.
YANG, S.-Y. see SIM, K.
YANO, Y. see MANT, T.G.K.
YEO, K.P. see CHAN, C.
YOON, Y.-R. see SHIN, J.-G.
ZAHLTEN, R. see MEYER, M.
ZECH, K. see NASSR, N.
ZGHEIB, N.K., FRYE, R.F., TRACY, T.S., ROMKES, M. & BRANCH, R.A. Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity: 477
ZHANG, M. see VELLA-BRINCAT, J.W.A.
ZHANG, M., HOLMAN, C.D.J., PREEN, D.B. & BRAMELD, K. Repeat adverse drug reactions causing hospitalization in older Australians: a population-based longitudinal study 1980–2003: 163
ZHAO, Q., JIANG, J., LI, X.M., LU, Z.S. & HU, P. Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects: 614
ZUEHLSDORF, M. see KUBITZA, D.